- Published on
Emergency and Acute Medicine – Schizophrenia
Schizophrenia is a chronic psychotic disorder characterized by delusions, hallucinations, disorganized thinking and behavior, negative symptoms, and cognitive impairment. The illness typically progresses through three phases: a premorbid phase with social withdrawal and decline in functioning, an active phase with prominent psychotic symptoms, and a residual phase marked by persistent cognitive and social deficits. Onset is usually in early adulthood (before age 30), and comorbid substance use—especially alcohol, cannabis, and stimulants—is common. Patients have a reduced life expectancy (by 12–25 years), largely due to cardiovascular disease, suicide (5–10%), and barriers to accessing medical care.
The exact cause remains unclear, but dysfunction in dopamine pathways is strongly implicated. There is a significant genetic component, with higher concordance in identical twins, and associations with conditions such as 22q11.2 deletion syndrome. Environmental and developmental factors—including prenatal infections, advanced paternal age, and cannabis use—may contribute. Schizophrenia is best understood as a multifactorial neurodevelopmental disorder with both biological and environmental influences.
Diagnosis is clinical and based on criteria (e.g., DSM) requiring at least two core symptoms for more than 6 months, including delusions, hallucinations, disorganized speech, disorganized/catatonic behavior, or negative symptoms (e.g., flat affect, apathy, social withdrawal). Patients often present to the emergency setting with acute psychosis, agitation, or behavioral disturbance, frequently related to medication noncompliance. A thorough evaluation must include screening for danger to self or others, substance use, and medical causes of psychosis (e.g., delirium, metabolic disturbances, neurologic disease), as schizophrenia does not typically impair orientation.
Emergency management prioritizes safety. Patients may be unpredictable or agitated, requiring a calm environment, verbal de-escalation, and sometimes physical or chemical restraints. First-line pharmacologic treatment for acute agitation includes antipsychotics such as haloperidol, often combined with benzodiazepines like lorazepam. Alternative agents include olanzapine, ziprasidone, and aripiprazole, though caution is required (e.g., avoid combining IM olanzapine with IV benzodiazepines due to risk of cardiopulmonary collapse). Continuous monitoring and a structured environment are essential.
Long-term treatment centers on antipsychotic medications. First-generation (typical) agents are effective but carry higher risk of extrapyramidal side effects, while second-generation (atypical) agents are better tolerated but associated with metabolic syndrome and weight gain. Clozapine is the most effective for treatment-resistant cases and reducing suicide risk but requires strict monitoring due to risk of agranulocytosis. Long-acting injectable formulations improve adherence in patients with frequent relapse due to noncompliance.
Disposition depends on patient safety and functional status. Hospital admission is indicated if the patient poses a danger to self or others, is unable to care for themselves, or has new-onset psychosis requiring evaluation. Stable patients with support and follow-up may be discharged with close psychiatric follow-up within 1 week.
Key clinical pearls include maintaining a high index of suspicion for medical causes of atypical psychosis, recognizing neuroleptic malignant syndrome in patients on antipsychotics, and understanding that early treatment improves long-term outcomes. Management is not only pharmacologic but also involves psychosocial support, therapy, and addressing comorbid conditions, especially substance use and cardiovascular risk factors.
0 Comments
